Vanguard Group Inc. Has $320.42 Million Stake in iRhythm Technologies, Inc. (NASDAQ:IRTC)

Vanguard Group Inc. boosted its holdings in iRhythm Technologies, Inc. (NASDAQ:IRTC) by 1.2% in the 4th quarter, HoldingsChannel.com reports. The firm owned 2,993,443 shares of the company’s stock after acquiring an additional 35,694 shares during the quarter. Vanguard Group Inc. owned 0.10% of iRhythm Technologies worth $320,418,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Kampmann Melissa S. grew its holdings in shares of iRhythm Technologies by 3.3% during the fourth quarter. Kampmann Melissa S. now owns 23,140 shares of the company’s stock valued at $2,477,000 after buying an additional 750 shares during the last quarter. Cim Investment Management Inc. increased its holdings in iRhythm Technologies by 122.5% during the 4th quarter. Cim Investment Management Inc. now owns 4,735 shares of the company’s stock worth $507,000 after purchasing an additional 2,607 shares in the last quarter. First Light Asset Management LLC raised its stake in shares of iRhythm Technologies by 72.7% in the fourth quarter. First Light Asset Management LLC now owns 152,063 shares of the company’s stock worth $16,277,000 after purchasing an additional 64,024 shares during the last quarter. Homestead Advisers Corp lifted its holdings in shares of iRhythm Technologies by 103.2% in the fourth quarter. Homestead Advisers Corp now owns 12,800 shares of the company’s stock valued at $1,370,000 after purchasing an additional 6,500 shares in the last quarter. Finally, Capital Research Global Investors boosted its position in shares of iRhythm Technologies by 5.1% during the fourth quarter. Capital Research Global Investors now owns 2,495,626 shares of the company’s stock valued at $267,132,000 after buying an additional 121,709 shares during the last quarter.

Insiders Place Their Bets

In related news, CAO Marc W. Rosenbaum sold 510 shares of the business’s stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $88.91, for a total transaction of $45,344.10. Following the sale, the chief accounting officer now directly owns 8,174 shares in the company, valued at approximately $726,750.34. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In other iRhythm Technologies news, EVP Sumi Shrishrimal sold 1,131 shares of the firm’s stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $88.91, for a total value of $100,557.21. Following the completion of the transaction, the executive vice president now directly owns 23,298 shares of the company’s stock, valued at approximately $2,071,425.18. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CAO Marc W. Rosenbaum sold 510 shares of the company’s stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $88.91, for a total transaction of $45,344.10. Following the completion of the transaction, the chief accounting officer now directly owns 8,174 shares in the company, valued at approximately $726,750.34. The disclosure for this sale can be found here. Company insiders own 0.68% of the company’s stock.

iRhythm Technologies Stock Up 3.1 %

IRTC stock opened at $107.64 on Friday. The stock has a fifty day moving average of $98.94 and a 200-day moving average of $106.84. iRhythm Technologies, Inc. has a fifty-two week low of $70.24 and a fifty-two week high of $124.11. The company has a market capitalization of $3.35 billion, a price-to-earnings ratio of -25.45 and a beta of 1.24. The company has a debt-to-equity ratio of 7.13, a quick ratio of 6.95 and a current ratio of 7.10.

iRhythm Technologies (NASDAQ:IRTC) last posted its earnings results on Thursday, May 2nd. The company reported ($1.47) earnings per share for the quarter, missing the consensus estimate of ($0.99) by ($0.48). The business had revenue of $131.93 million during the quarter, compared to analysts’ expectations of $128.87 million. iRhythm Technologies had a negative return on equity of 69.87% and a negative net margin of 25.33%. As a group, equities research analysts predict that iRhythm Technologies, Inc. will post -3.22 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts recently commented on the company. Needham & Company LLC increased their price target on iRhythm Technologies from $137.00 to $138.00 and gave the company a “buy” rating in a research report on Friday, May 3rd. Canaccord Genuity Group cut their price target on shares of iRhythm Technologies from $133.00 to $122.00 and set a “buy” rating on the stock in a report on Friday, May 3rd. Finally, Wolfe Research raised shares of iRhythm Technologies from a “peer perform” rating to an “outperform” rating and set a $115.00 price objective for the company in a research report on Thursday, June 20th. One equities research analyst has rated the stock with a sell rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $131.22.

About iRhythm Technologies

iRhythm Technologies, Inc, a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services.